3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Brain Neoplasms
5
Radiation Injuries
1
Oligodendroglioma
1
Neurotoxicity Syndromes
1
Neurofibromatosis 1
1
Multiple Myeloma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Glioma
1
Glioblastoma
1
Fatigue
1
Cytokine Release Syndrome
1
Colorectal Neoplasms
1
Cognitive Dysfunction
1
Breast Neoplasms
1
Astrocytoma
1
Interventions
Rituximab
47
Cyclophosphamide
26
fludarabine
13
ibrutinib
12
Doxorubicin
11
Vincristine
10
Etoposide
10
Cytarabine
10
Prednisone
9
Bortezomib
9
pembrolizumab
7
fludarabine phosphate
6
Lenalidomide
6
Inotuzumab Ozogamicin
6
obinutuzumab
5
Mycophenolic Acid
5
Melphalan
5
Carmustine
5
tositumomab I-131
4
ibritumomab tiuxetan
4
Tacrolimus
4
Prednisolone
4
Methotrexate
4
Gemcitabine
4
Bendamustine Hydrochloride
4
Antilymphocyte Serum
4
tocilizumab
3
tazemetostat
3
Whole-Body Irradiation
3
Vorinostat
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoma, B-Cell
×
Neuropsychological Tests
×
Clear all
NCT05510596
2024-08-09
MR-ICANS
University Hospital, Montpellier
Phase NA
Completed
25 enrolled